The Itch Drug That Couldn't Scratch the Surface

Incyte paid $750 million to acquire Escient Pharmaceuticals and its oral MRGPRX2 antagonist, EP262, which entered Phase Ib/II trials across multiple conditions. Septerna brought SEP-631, a slightly different flavor of MRGPRX2 blocker (a "negative allosteric modulator"), into Phase 1 testing. Novartis listed an MRGPRX2 inhibitor in its immunology pipeline. Blueprint Medicines published research on potent oral antagonists. Even GSK showed up in early screening work.

In other words, this wasn't some fringe idea. It was a legitimate therapeutic thesis backed by serious money and serious science. EVO756's back-to-back failures don't just kill one drug; they raise uncomfortable questions about whether MRGPRX2 is the right lock to pick at all.

If two well-designed mid-stage trials can't move the needle on eczema severity scores or hive symptoms, competitors now have a credibility problem. Every MRGPRX2 program in the pipeline just got harder to fund, harder to recruit for, and harder to pitch to regulators.

Wall Street's Weird Optimism

You'd expect analysts to run for the exits after a double failure. Surprisingly, many didn't.

Raymond James cut its price target on Evommune to $32 from $52 after the CSU failure, and then lowered it again to $18 from $32 after the atopic dermatitis failure. Leerink cut from $28 to $22. RBC went from $29 to $21 but kept an Outperform rating.

Why the lingering optimism? The answer likely involves Evommune's broader pipeline beyond MRGPRX2. Some analysts argued that lessons from these failures could inform future trial designs in other programs.

Call it faith. Call it sunk-cost bias. Either way, analysts are telling you they think there's something left in this company even after its lead program went to zero.

The Eczema Market Doesn't Need MRGPRX2 (For Now)

The good news for patients: the eczema pipeline is absolutely massive. Over 120 therapies from more than 100 companies are in development, and the disease has become one of the most active battlegrounds in all of dermatology.

JAK inhibitors like abrocitinib and upadacitinib already offer strong oral options. Biologics like dupilumab (targeting the IL-4/IL-13 pathway) remain the gold standard for moderate-to-severe cases. And newer mechanisms are flooding the clinic: IL-31 receptor blockers like nemolizumab specifically target itch, and TYK2 inhibitors represent yet another twist on the JAK-STAT pathway.

The unmet need is still real, though. Many patients don't respond well enough to existing drugs, can't tolerate them long-term, or live with persistent itch that current therapies only partially relieve. That's why the field keeps growing.

But MRGPRX2 was supposed to carve out a unique niche: upstream mast-cell control without touching IgE pathways. With that thesis now deeply wounded, companies will have to prove the biology works before anyone writes another big check.

What Comes Next

Evommune says it won't advance EVO756 in atopic dermatitis. Combined with the earlier CSU failure, that effectively ends the program in those indications. The question now shifts to the rest of the MRGPRX2 field.

Incyte's EP262 and Septerna's SEP-631 are still in the clinic. Their trials will carry extra scrutiny now. If those programs also stumble, MRGPRX2 could join the graveyard of targets that looked brilliant in preclinical models but couldn't deliver in humans. It wouldn't be the first time biology fooled everyone in the jump from lab bench to bedside.

For Evommune, the path forward depends on whatever else it has cooking. Analysts seem to think there's reason to stay interested; the stock is priced like a company in trouble, but the targets suggest a company with options.

For the broader eczema field, the lesson is familiar: elegant science doesn't guarantee clinical success. Sometimes you find the right key. Sometimes the lock was never going to open.

The Government Wants an AI Doctor for Your Heart

ARPA-H just bet $62.7 million that an AI can manage heart failure patients around the clock, prescribing drugs and ordering tests without waiting for a doctor. If it works, it could reshape how we treat the fastest-growing heart condition in America.